176 related articles for article (PubMed ID: 37229799)
21. [Ocrelizumab for treatment of multiple sclerosis].
Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP
Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD20 monoclonal antibodies in multiple sclerosis.
Moreno Torres I; García-Merino A
Expert Rev Neurother; 2017 Apr; 17(4):359-371. PubMed ID: 27718747
[TBL] [Abstract][Full Text] [Related]
23. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
24. Targeting CD20 in multiple sclerosis - review of current treatment strategies.
Chmielewska N; Szyndler J
Neurol Neurochir Pol; 2023; 57(3):235-242. PubMed ID: 36999373
[TBL] [Abstract][Full Text] [Related]
25. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
Caldito NG; Shirani A; Salter A; Stuve O
Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.
Florou D; Katsara M; Feehan J; Dardiotis E; Apostolopoulos V
Brain Sci; 2020 Oct; 10(10):. PubMed ID: 33092190
[TBL] [Abstract][Full Text] [Related]
27. Current evidence of rituximab in the treatment of multiple sclerosis.
Techa-Angkoon P; Siritho S; Tisavipat N; Suansanae T
Mult Scler Relat Disord; 2023 Jul; 75():104729. PubMed ID: 37148577
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
[TBL] [Abstract][Full Text] [Related]
29. Ofatumumab for relapsing forms of multiple sclerosis.
Gajofatto A; Orlandi R
Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
[TBL] [Abstract][Full Text] [Related]
30. Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab.
Haberli N; Coban H; Padam C; Montezuma-Rusca JM; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Feb; 48():102731. PubMed ID: 33450528
[TBL] [Abstract][Full Text] [Related]
31. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
Kaegi C; Wuest B; Crowley C; Boyman O
Front Immunol; 2021; 12():788830. PubMed ID: 35185862
[TBL] [Abstract][Full Text] [Related]
32. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.
Alvarez E; Longbrake EE; Rammohan KW; Stankiewicz J; Hersh CM
Mult Scler Relat Disord; 2023 Nov; 79():105009. PubMed ID: 37783194
[TBL] [Abstract][Full Text] [Related]
33. Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro.
Førde JL; Herfindal L; Myhr KM; Torkildsen Ø; Mollnes TE; Skrede S
Int Immunopharmacol; 2023 Nov; 124(Pt B):111021. PubMed ID: 37816262
[TBL] [Abstract][Full Text] [Related]
34. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.
Capasso N; Nozzolillo A; Scalia G; Lanzillo R; Carotenuto A; De Angelis M; Petruzzo M; Saccà F; Russo CV; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2021 Apr; 49():102802. PubMed ID: 33556652
[TBL] [Abstract][Full Text] [Related]
35. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody treatments for multiple sclerosis.
Rose JW; Foley J; Carlson N
Curr Neurol Neurosci Rep; 2008 Sep; 8(5):419-26. PubMed ID: 18713579
[TBL] [Abstract][Full Text] [Related]
37. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
38. The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis.
Wu X; Tan X; Zhang J; Wang Z; Wu W; Wang S; Liu Y; Wang Z
CNS Drugs; 2022 Nov; 36(11):1155-1170. PubMed ID: 36245023
[TBL] [Abstract][Full Text] [Related]
39. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
40. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
